Government Partnerships BARDA collaboration to supply MBP134 for high-risk exposures and WHO recognition of MBP134 as a leading candidate indicate strong government and international procurement potential for a broad-spectrum Ebola countermeasure.

Broad Spectrum Opportunity MBP134 targets multiple ebolaviruses, addressing unmet needs where no approved therapies exist, positioning Mapp as a go-to partner for outbreak response programs, international health agencies, and governments seeking stockpiled countermeasures.

Expanded Access Channel Mapp's expanded access policy creates a pathway to collaborate with clinicians, hospitals, and patient groups for compassionate use programs, generating early real world data and building demand ahead of potential approvals.

Partnership Track Record Past collaborations with ProBioGen and other networks demonstrate Mapp's ability to partner on cell line development and outbreak readiness, enabling co development or manufacturing partnerships with larger biopharma.

Commercial Readiness With a credible pipeline and history of programs, Mapp can pursue licensing, milestone based deals, or contract manufacturing arrangements to scale production and accelerate access for high priority markets.